CNS Pharmaceuticals appoints Steven O’Loughlin as CFO, Dylan Wenke as CBO

CNS Pharmaceuticals (CNSP) announced the Company’s recently appointed President and CEO, Rami Levin, in close alignment with the Board of Directors, has recruited key members to his new executive team. These new appointments, which will be effective March 2, 2026, will help drive the Company’s evolution. The Company announced the following appointments: Steven O’Loughlin as CFO; Eric Faulkner, MSc, MBA, as Chief Technology Officer; Dylan Wenke, MBA, as Chief Business Officer. Most recently, O’Loughlin served as CFO of Actinium Pharmaceuticals. Faulkner served in senior executive roles at IO Biotech, Homology Medicines, Shire and Biogen IDEC. Wenke held senior business development roles at Corbus Pharmaceuticals, Bluejay Therapeutics and EuMentis Therapeutics.